Private hospital operator Spire Healthcare on Monday said its no-deal Brexit plans mean risks of a medicines shortage are low once Britain leaves the EU.
Chief executive Justin Ash said the firm has been working with manufacturers and distributors for 18 months to ensure extra drugs are in place after October 31. The government’s Yellowhammer report has warned of potential disruption to supplies if there is no deal.
Ash said: “While we cannot completely rule out disruption, I believe my firm, as well as the NHS, is well prepared. Our patients should be reassured that we think the risk of pharmaceutical supplies running short is low.”
Spire, which runs 39 hospitals in the UK, posted a 3.4% sales rise to £491.6 million for the six months to June.
It made a pre-tax profit of £9.6 million, compared with a £2.2 million loss a year earlier.
The company, which provides consultant services and surgeries, saw better-than-expected revenues from NHS referrals.
It added that marketing campaigns helped it to attract more private customers.
